An ACE inhibitor or ARB, administered at non-hypotensive and hypotensive doses, reduces glomerular perivascular collagen deposition without altering the kidney/body weight ratio in young SHR during the development of HTN between 4–12 weeks of age [214]. This evidence concerns the gene ACE and hypertensive disorder.